Description

Indication & Scope

Klacid® is a prescription macrolide antibiotic indicated for the treatment of infections caused by clarithromycin-susceptible microorganisms, including upper and lower respiratory tract infections, skin and soft tissue infections, Helicobacter pylori eradication therapy, and atypical bacterial infections.

Mechanism: Clarithromycin binds to the bacterial 50S ribosomal subunit and inhibits protein synthesis, suppressing bacterial growth.
Drug class: Second-generation macrolide antibacterial agent.
Clinical use: Treatment of susceptible respiratory infections, atypical infections, and combination therapy for H. pylori eradication.

Specification

Generic Name	Clarithromycin Tablets
Brand Name	Klacid®
Ingredient	Clarithromycin
Dosage Form	Tablet
Package	0.25 g/tablet, 8 tablets/carton
Conditions Treated	Respiratory tract infections, skin and soft tissue infections, Helicobacter pylori infection, atypical bacterial infections
Taboos	Hypersensitivity to clarithromycin, erythromycin, other macrolides, or any component of the product; severe liver impairment; concomitant use with contraindicated CYP3A4-related drugs
Place of origin	China
Prescription type	Prescription Drug (Rx)
Storage Conditions	Store below 25°C in a dry place. Protect from moisture and light.
Manufacturer	Abbott Laboratories (Shanghai) Co., Ltd.
Registration Authority	National Medical Products Administration (NMPA), China
Approval Number	H20033044
Approval Date	December 18, 2023
Shelf Life	36 months

How to use ?

Recommended Dose: Adults: Common infections: 250 mg every 12 hours. Severe infections: 500 mg every 12 hours. Usual treatment duration: 7–14 days. For Helicobacter pylori eradication: 500 mg twice daily combined with proton pump inhibitor and another antibacterial agent for 10–14 days.

Time: Take orally with or without food. Swallow tablets whole with water.

Instructions for use: Complete the prescribed course. Dose adjustment is required in severe renal impairment. Do not use alone for H. pylori eradication because monotherapy rapidly induces resistance.

Interaction: Clarithromycin strongly inhibits CYP3A4. Avoid combination with simvastatin, lovastatin, ergot derivatives, cisapride, pimozide, and astemizole. Monitor patients receiving warfarin, digoxin, or other CYP3A4 substrates.

Side effects: Common adverse reactions include nausea, diarrhea, abdominal discomfort, vomiting, taste disturbance, headache, dizziness, rash, and elevated liver enzymes. Serious adverse reactions may include severe allergic reactions, QT prolongation, liver injury, Clostridioides difficile–associated diarrhea, severe skin reactions, and blood abnormalities.

Important Notice

This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indication, and regional regulatory requirements.

Packaging & Shipping

Packaging

Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.

Shipping Methods

Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.

Export Support

Certificate of Analysis

GMP Certificate

Commercial Invoice

Packing List & CPP

Cold Chain Logistics

Customs Documentation

Scientific and regulatory sources

1.WHO References

2.NMPA

3.FDA

4.EMA

FAQ

What is Klacid® used for?

It is used to treat susceptible bacterial infections, including respiratory infections, skin infections, atypical infections, and as part of combination therapy for H. pylori eradication.

Can Klacid® treat viral infections?

No. It is an antibacterial medicine and does not treat viral infections such as common cold or influenza.

How should Klacid® be taken?

It is usually taken twice daily according to the prescribed dose. The treatment duration depends on the infection type.

Can Klacid® be used for Helicobacter pylori infection alone?

No. It must be combined with acid-suppressing therapy and another antibacterial agent to achieve effective eradication.